Algorithmiq, a European quantum algorithm company focused on life sciences, is partnering with Quantum Circuits, Inc. to enhance drug discovery using the full-stack quantum computing system Aqumen Seeker. This collaboration enables more accurate chemistry calculations by leveraging Seeker’s industry-first dual-rail qubits with built-in error detection.
By integrating Quantum Circuits’ technology, Algorithmiq aims to develop quantum algorithms that improve molecular simulations, such as enzyme pharmacokinetics modeling, overcoming classical computing limitations. The partnership aligns with Quantum Circuits’ “correct first, then scale” approach, ensuring reliable calculations essential for pharmaceutical innovation. The Aqumen Seeker platform currently contains 8 dual-rail qubits, however Algorithmiq’s software is being designed to easily scale as the number of available qubits increase in future machines.
Quantum Circuits, founded by Yale researchers, recently emerged from stealth mode with a $60M Series B funding round and the launch of Aqumen Seeker. The company’s error detection technology is designed to advance quantum computing’s commercial readiness, supporting applications in life sciences and beyond.
For information, visit Quantum Circuit’s website here.
February 12, 2025
Leave A Comment